Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 plus fulvestrant versus placebo plus fulvestrant in HR-positive HER2-negative advanced or metastatic breast cancer after mTOR inhibitor treatment
2012-002571-34Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing BKM120 plus fulvestrant with Placebo plus fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Jul 2012; status: terminated.
02
Drugs
buparlisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-002571-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002571-34.